Compare AEVA & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | ABSI |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.8M |
| IPO Year | 2020 | 2021 |
| Metric | AEVA | ABSI |
|---|---|---|
| Price | $14.28 | $10.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $30.00 | $14.40 |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $78.97 | $39.03 |
| Revenue Next Year | $124.76 | $314.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.83 | $2.24 |
| 52 Week High | $31.30 | $12.06 |
| Indicator | AEVA | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 62.14 |
| Support Level | $13.95 | $8.17 |
| Resistance Level | $14.30 | $11.26 |
| Average True Range (ATR) | 0.81 | 0.71 |
| MACD | 0.05 | 0.16 |
| Stochastic Oscillator | 11.26 | 87.30 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.